- Home
- RGC vs ACHV Comparison
RGC vs ACHV Comparison
Compare RGC & ACHV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RGC | ACHV |
|---|---|---|
| Founded | 2014 | N/A |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.8B | 239.0M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | RGC | ACHV |
|---|---|---|
| Price | $25.35 | $4.45 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $15.50 |
| AVG Volume (30 Days) | 287.2K | ★ 546.8K |
| Earning Date | 10-24-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.09 | $1.84 |
| 52 Week High | $83.60 | $5.78 |
Technical Indicators
Market Signals| Indicator | RGC | ACHV |
|---|---|---|
| Relative Strength Index (RSI) | 78.40 | 49.77 |
| Support Level | $16.30 | $4.25 |
| Resistance Level | $18.10 | $4.52 |
| Average True Range (ATR) | 1.92 | 0.22 |
| MACD | 0.98 | -0.03 |
| Stochastic Oscillator | 83.21 | 31.54 |
Price Performance
Historical ComparisonAbout RGC Regencell Bioscience Holdings Limited
Regencell Bioscience Holdings Ltd is a bioscience company focusing on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degenerations, specifically ADHD and ASD, and infectious diseases affecting people's immune systems.
About ACHV Achieve Life Sciences Inc.
Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for niceon.